Medulloblastomas are the most common malignant brain tumour of childhood. They most commonly present as midline masses in the roof of the 4th ventricle with associated mass effect and hydrocephalus. Treatment typically consists of surgical resection, radiation therapy, and chemotherapy, with the prognosis strongly influenced by surgical resection, the presence of CSF metastases at the time of diagnosis, and expression of the c-erbB-2 (HER2/neu) oncogene.
Although medulloblastoma has been classically thought of as a single entity it is becoming increasingly evident that there are a number of distinct molecular subgroups with, albeit overlapping, clinical, histological and imaging features 8. This has been reflected in the 2016 update of the WHO classification of CNS tumours, which recognizes four molecular subgroups.
These molecular subgroups have been named WNT, SHH, Group 3 and Group 4 8. Perhaps counterintuitively what most of us think of as the typical medulloblastoma (a midline tumour in early childhood) is group 4. Further information on the subtypes of medulloblastoma is available in the links below and in the article classification of medulloblastomas.
Overall medulloblastomas account for 12-25 % of all paediatric CNS tumours, and 30-40% of paediatric posterior fossa tumours 1,7. They are also seen in adults but only account for 0.4-1.0% of adult brain tumours 1. Since there are many more adults than children, 14-30% of all medulloblastomas are found in adults.
Taken as a group, there is a moderate male predilection with a M:F ratio of 2:1, although this is only true of group 3 and 4 tumours 8.
They usually present in childhood with 77% of cases before the age of 19. The median age of diagnosis is 9 years. When diagnosed in adulthood, they typically present in the 3rd and 4th decades and are more likely to arise in atypical locations (see below). When they present in adulthood, there is often a better prognosis.
Importantly age of presentation and gender ratio is influenced by tumour genomics 7-9:
- children and adults (not seen in infancy)
- M:F 1:1
- infants and adults (rare in children)
- M:F 1:1
- Group 3
- infants and children (rare in adults)
- M > F
- Group 4
- typically children (rare in infants)
- M:F 2:1
The growth of these very cellular tumours is often rapid and accounts for their relatively rapid clinical onset. Typically, presentation occurs over a few weeks with features that are dominated by symptoms of raised intracranial pressure as a result of obstructive hydrocephalus 7.
In approximately 40% of patients, there is evidence of CSF seeding at the time of diagnosis 7.
The tumours, in general, tend to be extremely cellular and is an example of a small round blue cell tumour which results in predictable imaging features. They are categorised as CNS primitive neuroectodermal tumours (WHO grade IV).
Medulloblastomas are associated with a number of syndromes, including:
- Coffin-Siris syndrome
- Cowden syndrome
- Gardner syndrome
- Gorlin syndrome
- Li-Fraumeni syndrome
- Rubinstein-Taybi syndrome
- Turcot syndrome
The radiographic features are strongly influenced by the histological type and molecular subtype of the tumour. Many of the imaging characteristics can, however, be remembered by thinking of medulloblastoma as a small round blue cell tumour.
Overall the vast majority (94%) of medulloblastomas arise in the cerebellum and the majority of these, from the vermis (75%). They tend to protrude into the fourth ventricle from its roof, and may even grow directly into the brainstem 1,7. This pattern is particularly common in group 3 and group 4, and in some SHH subgroup tumours 10.
Other areas are less common and are seen more frequent in older children and adults. In such cases, the tumour is also more likely to be poorly marginated and demonstrate larger cyst formation 7. Adult medulloblastomas are usually located laterally, in the cerebellar hemispheres, with only 28% centred in the vermis; these are most commonly of the SHH subgroup 10.
Cerebellar peduncle epicentre is almost exclusively seen in the relatively indolent WNT subgroup 8-10.
On CT, medulloblastomas often appear as a mass arising from the vermis, resulting in effacement of the fourth ventricle / basal cisterns and obstructive hydrocephalus. They can also occur more laterally in the cerebellum.
They are usually hyperdense (90%) and cysts formation/necrosis is common (40-50%), especially in older patients. Calcification is seen in 10-20% of cases 7.
Enhancement is present in over 90% of cases and is usually prominent 7.
- hypointense to grey matter
T1 C+ (Gd)
- overall 90% enhance, often heterogeneously
- group 4 tumours tend to enhance less 10
- overall are iso to hyperintense to grey matter
- heterogeneous due to calcification, necrosis and cyst formation
- surrounding oedema is common 10
- high DWI signal ("restricted diffusion")
- low ADC values (lower than normal cerebellum e.g. ~550 x 10-6 mm2/s) 11
- elevated choline
- decreased NAA
- may show a taurine peak 5
MRI is able to delineate the fourth ventricle and subarachnoid space to a much greater degree than CT. Although medulloblastomas project into the fourth ventricle, unlike ependymomas they do not usually extend into the basal cisterns 7.
As CSF seeding is common at presentation, imaging with contrast of the whole neuraxis is recommended to identify drop metastases and leptomeningeal spread. Although rare, extraneural spread is reported.
Predicting molecular subgroup from imaging
So if all this sounds confusing, that's because it is. Molecular subgroups, histology, location, appearance and demographics all interact, but this notwithstanding, you can make some fairly robust predictions based on imaging when taking all of these together. Location is the key to this approach.
- cerebellar peduncle
- very likely WNT subgroup and therefore best prognosis
- cerebellar hemisphere
- very likely SHH subgroup and therefore intermediate prognosis
- likely desmoplastic/nodular/medulloblastoma with extensive nodularity (MBEN)
- may be group 3, group 4 or SHH
- typically infants with a poorly defined tumour, with prominent enhancement, likely group 3 (or SHH) and therefore worst prognosis
- typically children with well-defined tumours, with mild or no enhancement, likely group 4 and therefore slightly better prognosis
- adults with variably defined and variably enhancing tumours, are likely SHH (or group 4)
Treatment and prognosis
Treatment typically consists of surgical resection, radiation therapy, and chemotherapy. In general, the tumours are quite radiosensitive.
Prognosis depends on complete surgical resection, and presence of CSF metastases at the time of diagnosis, which is generally common in infants and children (~25%) and uncommon in adults (~2%) 1.
Expression of the c-erbB-2 (HER2/neu) oncogene is useful in the staging of medulloblastomas. Increased c-erbB-2 expression reflects an increase in the proliferative activity of a tumour (widely used in breast cancer staging).
- no CSF metastases, complete surgical resection and negative c-erbB-2 expression: 5-year-survival 100%
- no CSF metastases, complete surgical resection and positive c-erbB-2 expression: 5-year-survival 54%
- CSF metastases and/or incomplete surgical resection: 5-year-survival 20%
New genomic classification is also useful in predicting prognosis 7-9:
- WNT: very good
- SHH: infants good, others intermediate
- group 3: poor
- group 4: intermediate
In the paediatric population consider:
- usually arises from the floor of the 4th ventricle
- typically squeezes out the foramen of Luschka
- choroid plexus papilloma (CPP) : more common in lateral ventricles in children
- pilocytic astrocytoma
- atypical teratoid/rhabdoid tumour
- brainstem glioma (exophytic)
In the adult population consider:
- 1. Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics. 23 (6): 1613-37. doi:10.1148/rg.236035168 - Pubmed citation
- 2. Bal MM, Das radotra B, Srinivasan R et-al. Does c-erbB-2 expression have a role in medulloblastoma prognosis? Indian J Pathol Microbiol. 2006;49 (4): 535-9. Pubmed citation
- 3. Muss HB, Thor AD, Berry DA et-al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 1994;330 (18): 1260-6. N. Engl. J. Med. (link) - Pubmed citation
- 4. Barkovich AJ. Pediatric neuroimaging. Raven Pr. (2000) ISBN:078171740X. Read it at Google Books - Find it at Amazon
- 5. Panigrahy A, Krieger MD, Gonzalez-gomez I et-al. Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am J Neuroradiol. 2006;27 (3): 560-72. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 6. Ketonen L, Hiwatashi A, Sidhu R. Pediatric brain and spine, an atlas of MRI and spectroscopy. Springer Verlag. (2005) ISBN:3540213406. Read it at Google Books - Find it at Amazon
- 7. Taylor MD, Northcott PA, Korshunov A et-al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123 (4): 465-72. doi:10.1007/s00401-011-0922-z - Free text at pubmed - Pubmed citation
- 8. Kool M, Korshunov A, Remke M et-al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123 (4): 473-84. doi:10.1007/s00401-012-0958-8 - Free text at pubmed - Pubmed citation
- 9. DeSouza RM, Jones BR, Lowis SP et-al. Pediatric medulloblastoma - update on molecular classification driving targeted therapies. Front Oncol. 2014;4: 176. doi:10.3389/fonc.2014.00176 - Free text at pubmed - Pubmed citation
- 10. Perreault S, Ramaswamy V, Achrol AS et-al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2014;35 (7): 1263-9. doi:10.3174/ajnr.A3990 - Pubmed citation
- 11. Pierce TT, Provenzale JM. Evaluation of apparent diffusion coefficient thresholds for diagnosis of medulloblastoma using diffusion-weighted imaging. The neuroradiology journal. 27 (1): 63-74. doi:10.15274/NRJ-2014-10007 - Pubmed
Posterior fossa tumour